MONTRÉAL, JUNE 3, 2020 – ExCellThera Inc., a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today new appointments to its Board of Directors and Scientific Advisory Board as it prepares for the next phase of growth.
Michael Hanley, CPA, CA, joins ExCellThera’s Board of Directors, while Andromachi (Machi) Scaradavou, MD, and Steven Woodside, PhD, join the Scientific Advisory Board.
“Michael, Machi and Steven are seasoned world-class leaders in their fields of financial management, bone marrow transplant and cell separation engineering, and are bringing their expertise to ExCellThera at this important time as we advance our clinical program and scale operations,” said Dr. Guy Sauvageau, CEO and founder of ExCellThera. “Our leadership team is looking forward to working with them and leveraging their skills and experience to deliver on key clinical, scientific and business objectives.”
Michael Hanley is an independent director with executive experience in financial and operations management with leading global public companies. He currently serves as non-executive director and as Chair of Audit Committees with three global public companies. Prior to this, he held senior management positions for close to 20 years with leading Canadian companies, including roles as Senior Vice-President, Operations and Strategic Initiatives, Business Group President and Chief Financial Officer. Mr. Hanley holds the chartered professional accountant (CPA, CA) designation since 1987.
Andromachi (Machi) Scaradavou is a Transplant Physician at Memorial Sloan-Kettering Cancer Center in New York. She is a pediatric hematologist and oncologist with extensive experience in cord blood transplants to treat babies, children and young adults with leukemia, lymphoma, and other cancers and blood diseases. She also has profound expertise in cord blood banking and quality evaluation of cord blood products.
Steven Woodside is Senior Director, Engineering at Notch Therapeutics in Vancouver and prior to that held senior development positions at STEMCELL Technologies. He has more than 20 years of experience in science and technology research and development in large multinational and biotechnology companies. Dr. Woodside has a PhD in chemical engineering from the University of British Columbia.
About ExCellThera Inc.
ExCellThera is a clinical-stage cell and molecular medicine biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for use in novel one-time curative therapies for patients with hematologic malignancies, autoimmune and other diseases. ExCellThera’s most advanced technology, ECT-001 Cell Therapy, combines a proprietary small molecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its portfolio of products, as well as supporting best-in-class clinical trials. www.excellthera.com
